| dc.contributor.author | Makowska, Marta | |
| dc.contributor.author | Jasiński, Łukasz | |
| dc.date.accessioned | 2017-06-27T09:46:02Z | |
| dc.date.available | 2017-06-27T09:46:02Z | |
| dc.date.issued | 2017 | |
| dc.identifier.issn | 1899-2226 | |
| dc.identifier.uri | http://hdl.handle.net/11089/22028 | |
| dc.description.abstract | The article raises issues of transparency in relationships between doctors and drug manufacturers. It indicates how important it is as a way for physicians and the pharmaceutical industry to regain public trust. The manuscript will define the concept of disclosure. It will discuss in detail The Physician Payment Sunshine Act from the U.S., which imposes a legal obligation on pharmaceutical companies to disclose their relationships with doctors and university hospitals. The article will also show the diverse regulation of disclosure in different countries of the European Union. The situation in Poland will be also described. In the summary, there will be a discussion about the importance of disclosure for patients and the advantages and disadvantages of such regulations for physicians and drug manufacturers. | en_GB |
| dc.language.iso | pl | pl_PL |
| dc.publisher | Wydawnictwo Uniwersytetu Łódzkiego | pl_PL |
| dc.relation.ispartofseries | Annales. Etyka w życiu gospodarczym;1 | |
| dc.subject | conflict of interest | en_GB |
| dc.subject | disclosure | en_GB |
| dc.subject | ethical standard | en_GB |
| dc.subject | pharmaceutical industry | en_GB |
| dc.title | Znaczenie „przejrzystości” w relacjach lekarzy z firmami farmaceutycznymi | pl_PL |
| dc.title.alternative | The Importance of ‘Disclosure’ in Relationships between Physicians and Pharmaceutical Companies | en_GB |
| dc.type | Article | pl_PL |
| dc.rights.holder | © Copyright by Authors, Łódź 2017; © Copyright for this edition by Uniwersytet Łódzki, Łódź 2017 | pl_PL |
| dc.page.number | [95]-109 | |
| dc.contributor.authorAffiliation | Warsaw University of Life Sciences, Faculty of Social Sciences, Department of Sociology | |
| dc.contributor.authorAffiliation | Maria Curie Sklodowska University of Lublin, Faculty of Economics | |
| dc.identifier.eissn | 2353-4896 | |
| dc.references | Advamed, The Physician Sunshine Act and You, http://advamed.org/res.download/60. | pl_PL |
| dc.references | Agrawal S., N. Brennan, P. Budetti, The Sunshine Act–effects on physicians, „New England Journal of Medicine” 2013, vol. 368, nr 22, s. 2054–2057. | pl_PL |
| dc.references | American Medical Association, Sunshine Act FAQs, http://www.ama-assn.org/ama/pub/advocacy/topics/sunshine-act-and-physician-financial-transparency-reports/sunshineact-faqs.page?. | pl_PL |
| dc.references | Campbell E.C., R.L. Gruen, J. Mountford, L.G. Miller, P.D. Cleary, D. Blumenthal, A National Survey of Physician – Industry Relationships, „The New England Journal of Medicine” 2007, nr 356, s. 1746. | pl_PL |
| dc.references | CBOS, Prestiż zawodów, Warszawa 1999. | pl_PL |
| dc.references | CBOS, Prestiż zawodów, Warszawa 2013. | pl_PL |
| dc.references | CBOS, Społeczne oceny uczciwości i rzetelności zawodowej, Warszawa 2016. | pl_PL |
| dc.references | Ciadini R., Wywieranie wpływu na ludzi. Teoria i praktyka, GWP, Gdańsk 2003. | pl_PL |
| dc.references | CMS, Fact Sheet for Physcians, https://www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician-Payment-Transparency-Program/Downloads/Physician-fact-sheet.pdf. | pl_PL |
| dc.references | CMS, Open Payments Data Summary, https://openpaymentsdata.cms.gov/summary. | pl_PL |
| dc.references | The CMS Blog, CMS Releases Third Year of Open Payments Data, https://blog.cms.gov/2016/06/30/cms-releases-third-year-of-open-payments-data/. | pl_PL |
| dc.references | Comparison of the French sunshine act. (Loi Bertrand Law) and the US Sunshine Act, https://pharmapromotional.wordpress.com/2013/09/30/comparison-of-the-french-sunshine-act-loi-bertrand-law-and-the-us-sunshine-act/. | pl_PL |
| dc.references | Hajnosz I., H. Wróblewski, To jak pan korumpował lekarza, „Gazeta Wyborcza” 2007, nr 182, s. 6. | pl_PL |
| dc.references | Halperin E.C., P. Hutchison, R.C. Barrier Jr, A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers, „International Journal of Radiation Oncology* Biology* Physics” 2004, nr 59(5), s. 1479. | pl_PL |
| dc.references | INFARMA, Czym jest Kodeks Przejrzystości, http://www.kodeksprzejrzystosci.pl/kodeksprzejrzysto%C5%9Bci/. | pl_PL |
| dc.references | INFARMA, Kodeks Dobrych Praktyk Przemysłu Farmaceutycznego, http://www.infarma.pl/assets/files/etyka/KodeksDobrychPraktyk_Wyd_2_201014_PL.PDF. | pl_PL |
| dc.references | INFARMA, Kodeks przejrzystości, http://www.kodeksprzejrzystosci.pl/assets/files/etyka/Kodeks_Przejrzystosci_wydanie_5.pdf. | pl_PL |
| dc.references | Kruczkowska M., Koncerny farmaceutyczne korumpują Chiny. Jeden się pokajał, „Gazeta Wyborcza” 2013, nr 172, s. 8. | pl_PL |
| dc.references | Lieb K., A. Scheurich, Contact Between Doctors and the Pharmaceutical Industry, Their Perceptions, and the Effects on Prescribing Habits, „PLoS One” 2014, nr 9 (10), doi: 10.1371/journal.pone.0110130. | pl_PL |
| dc.references | Lizut M., Jak ustawić lekarza, „Gazeta Wyborcza” 2006, nr 120, s. 4. | pl_PL |
| dc.references | Makowska M., Etyczne standardy marketingu farmaceutycznego, CeDeWu, Warszawa 2010. | pl_PL |
| dc.references | Makowska M., Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce, Wydawnictwo SGGW, Warszawa 2016. | pl_PL |
| dc.references | Makowska M., Rola śledztw dziennikarskich w kreowaniu etycznych standardów marketingu farmaceutycznego, „Prakseologia” 2012, nr 152. | pl_PL |
| dc.references | Orlowski J.P., L. Wateska, The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch, „Chest” 1992, nr 102(1), s. 270–271. | pl_PL |
| dc.references | PolicyMed, Open Payments Data Summary, http://www.policymed.com/2016/06/open-payments-2015-data-released.html. | pl_PL |
| dc.references | Pham-Kanter G.G., Alexander C., Nair K., Effect of Physician Payment Disclosure Laws on Prescribing, „Archives of Internal Medicine” 2012, nr 172, s. 819. | pl_PL |
| dc.references | Prozilo Life Sciences, Ready or Not, Full Speed Ahead for the Global Transparency Movment, https://s3-us-west-2.amazonaws.com/porzio/media/1432/porziols-whitepaper_august-2015.pdf. | pl_PL |
| dc.references | Rabij M., Lekarz zdalnie sterowany, „Newsweek Polska” 2014, nr 2, s. 32–35. | pl_PL |
| dc.references | Raport przejrzystości, http://www.kodeksprzejrzystosci.pl/raporty/. | pl_PL |
| dc.references | Snapshot of sunshine rules in EU countries for the pharmaceutical industry, http://documents.jdsupra.com/beee41ce-968c-484e-9eca-73d39615efb1.pdf. | pl_PL |
| dc.references | Szymborski T., Kasa fundacji zabytków, „Rzeczpospolita” 2003, nr 123, s. A1–A4. | pl_PL |
| dc.references | Vox, Doctors and hospitals got at least $3.5 billion from industry in just five months, http://www.vox.com/2014/9/30/6868897/you-can-now-search-for-your-doctors-pharmapayments-online-sunshine-act. | pl_PL |
| dc.references | Wazana A, Physicians and the Pharmaceutical Industry. Is a Gift Ever Just a Gift?, „Journal of American Medical Association” 2000, vol. 283, nr 3, s. 375. | pl_PL |
| dc.references | Zverejňovanie na základe zákona č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach, http://www.nczisk.sk/Medicinska-statistika/Zverejnovanie_na_zaklade-zakona_362-2011_liekoch_zdravotnickych_pomockach/Stranky/default.aspx. | pl_PL |
| dc.contributor.authorEmail | marta_makowska@sggw.pl | |
| dc.contributor.authorEmail | lukasz.jasinski@poczta.umcs.lublin.pl | |
| dc.identifier.doi | 10.18778/1899-2226.20.1.07 | |
| dc.relation.volume | 20 | pl_PL |
| dc.subject.jel | I18 | |
